Swiss Economicblogs.org
The last few years haven’t done wonders for the reputation of the pharmaceutical industry. In 2015, Turing Pharmaceuticals faced public outrage after hiking the price of Daraprim, a drug used to treat the parasitic disease toxoplasmosis in vulnerable populations such as pregnant women and AIDS patients, by more than 5,000 percent. This year, Mylan is embroiled in an ongoing controversy after the price of its emergency allergy treatment EpiPen increased sixfold in under a decade. Meanwhile,...
Read More »Debunking the Drug Pricing Scare
